ABCL — AbCellera Biologics Share News
0.000.00%
- $3.75bn
- $2.99bn
- $75.13m
Canada's AbCellera Q3 revenue beats analyst estimates
Factbox: Pharma sector doubles down on AI to slash costs, timelines
U.S. STOCKS ON THE MOVE-Tapestry, Cisco, Sandisk
U.S. STOCKS ON THE MOVE-EnerSys, Netflix, Salesforce
U.S. STOCKS ON THE MOVE-Cerebras, Madison Square Garden Sports
AbCellera dips after $200 mln share sale for menopause drug
Brief: AbCellera Announces Pricing Of Oversubscribed $200 Million Public Offering Of Common Shares
AbCellera slips after launching $200 mln stock offering to fund menopause drug
Brief: AbCellera Announces Proposed Public Offering Of Common Stock And Pre-Funded Warrants
U.S. STOCKS ON THE MOVE-Microsoft, Coastal Financial, Eli Lilly
U.S. STOCKS ON THE MOVE-Microsoft, Coastal Financial
AbCellera gains as experimental drug reduces hot flashes in mid-stage trial
U.S. STOCKS ON THE MOVE-SpaceX, AAON, Vertex Pharma
U.S. STOCKS ON THE MOVE-Apple, Barrick Mining, AbCellera Biologics
AbCellera gains as experimental drug reduces hot flashes in mid-stage trial
Brief: AbCellera Announces Positive Top-Line Phase 2 Clinical Trial Results For ABCL635, Demonstrating Significant Reduction In Frequency And Severity Of Vasomotor Symptoms And A Favorable Tolerability Profile
AbCellera's menopause drug cuts hot flashes in mid-stage trial, shares surge (updated)
AbCellera's menopause drug reduces hot flashes in mid-stage trial
AbCellera Biologics Inc. reports results for the quarter ended June 30 - Earnings Summary